Literature DB >> 15383867

Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas.

Melanie L Richards1, Paul Gauger, Norman W Thompson, Thomas J Giordano.   

Abstract

Enterochromaffin-like (ECL) tumors are documented in patients with hypergastrinemia secondary to chronic atrophic gastritis or with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1 (ZES-MEN-1). In patients with ECL tumors and atrophic gastritis, normogastrinemia after antrectomy has resulted in resolution, regression, or stabilization of ECL tumors. The natural history of ECL tumors associated with ZES-MEN-1 following normalization of gastrin levels after gastrinoma resection has not been previously reported. The purpose of this study was to determine the course of ECL tumors in patients with ZES-MEN-1 following normalization of serum gastrin levels after gastrinoma resection. Two patients with ZES-MEN-1 had biopsy-proven ECL tumors on endoscopic evaluation. They then underwent surgical exploration that included distal pancreatectomy, enucleation of pancreatic head tumors, duodenotomy with excision of submucosal tumors, and peripancreatic lymphadenectomy. Gastric ECL tumors larger than 1.0 cm were locally excised. Patients underwent long-term follow-up with biochemical and endoscopic surveillance. Normogastrinemia was achieved and sustained following gastrinoma resection in two patients with ZES-MEN-1. Periodic endoscopic surveillance over a 6-year period showed complete resolution of the ECL tumors. The development of ECL tumors associated with ZES-MEN-1 is multifactorial. Studies identified a genetic influence on tumor growth with loss of heterozygosity at the MEN-1 gene locus in ECL tumors. The resolution of ECL tumors in ZES-MEN-1 patients who are normogastrinemic indicates that an elevated gastrin level is a primary initiator for development of these tumors. Therefore both genetic defects and hypergastrinemia are causative agents. Normalization of serum gastrin levels is critical for the prevention of aggressive forms of ECL tumors.

Entities:  

Mesh:

Year:  2004        PMID: 15383867     DOI: 10.1007/s00268-004-7345-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  40 in total

1.  Treatment of type II gastric carcinoid tumors with somatostatin analogues.

Authors:  P Tomassetti; M Migliori; G C Caletti; P Fusaroli; R Corinaldesi; L Gullo
Journal:  N Engl J Med       Date:  2000-08-24       Impact factor: 91.245

Review 2.  Histopathological classification of nonantral gastric endocrine growths in man.

Authors:  E Solcia; C Bordi; W Creutzfeldt; Y Dayal; A D Dayan; S Falkmer; L Grimelius; N Havu
Journal:  Digestion       Date:  1988       Impact factor: 3.216

3.  Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I.

Authors:  C Bordi; A Falchetti; C Azzoni; T D'Adda; G Canavese; A Guariglia; D Santini; P Tomassetti; M L Brandi
Journal:  Am J Surg Pathol       Date:  1997-09       Impact factor: 6.394

4.  Endocrine cells in the human oxyntic mucosa. A histochemical study.

Authors:  M Simonsson; S Eriksson; R Håkanson; T Lind; H Lönroth; L Lundell; D T O'Connor; F Sundler
Journal:  Scand J Gastroenterol       Date:  1988-11       Impact factor: 2.423

5.  Properties of a new system of amine-storing cells in the gastric mucosa of the rat.

Authors:  R Håkanson; B Lilja; C Owman
Journal:  Eur J Pharmacol       Date:  1967-05       Impact factor: 4.432

6.  Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study.

Authors:  F Gibril; J C Reynolds; I A Lubensky; P K Roy; P L Peghini; J L Doppman; R T Jensen
Journal:  J Nucl Med       Date:  2000-10       Impact factor: 10.057

7.  Histamine secretion from rat enterochromaffinlike cells.

Authors:  C Prinz; M Kajimura; D R Scott; F Mercier; H F Helander; G Sachs
Journal:  Gastroenterology       Date:  1993-08       Impact factor: 22.682

Review 8.  Gastric endocrine cell proliferation and fundic argyrophil carcinoid tumors in patients with the Zollinger-Ellison syndrome.

Authors:  G Cadiot; T Lehy; M Mignon
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

9.  Findings and long-term results of parathyroid surgery in multiple endocrine neoplasia type 1.

Authors:  P Hellman; B Skogseid; C Juhlin; G Akerström; J Rastad
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

10.  Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats.

Authors:  R Håkanson; Y Tielemans; D Chen; K Andersson; H Mattsson; F Sundler
Journal:  Gastroenterology       Date:  1993-07       Impact factor: 22.682

View more
  9 in total

1.  Management of gastric carcinoids (neuroendocrine neoplasms).

Authors:  Mark Kidd; Bjorn I Gustafsson
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 2.  [Gastric neuroendocrine tumors. Endoscopic and surgical treatment].

Authors:  M B Niederle; B Niederle
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

3.  Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience.

Authors:  Yusuf Karakaş; Şahin Laçin; Olcay Kurtulan; Ece Esin; Veli Sunar; Cenk Sökmensüer; Saadettin Kılıçkap; Şuayib Yalçin
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

4.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059

5.  Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells.

Authors:  E Hofsli; L Thommesen; F Yadetie; M Langaas; W Kusnierczyk; U Falkmer; A K Sandvik; A Laegreid
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

6.  Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.

Authors:  Lynsey M Daniels; Marian Khalili; William F Morano; Michaela Simoncini; Beth C Mapow; Andrea Leaf; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2019-12-09       Impact factor: 2.754

Review 7.  Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1.

Authors:  Göran Akerström; Peter Stålberg; Per Hellman
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 8.  Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

Review 9.  Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?

Authors:  Denis M McCarthy
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.